China Medical Tech. (CMED) Receives SFDA Approval for SPR-Based Analysis System
More News related to CMED
- China Medical Technologies to Participate Investor Conferences in March 2010
- China Medical Technologies to Announce Unaudited Financial Results for the Third Fiscal Quarter Ended December 31, 2009 on March 3, 2010
- Halter USX China Index Up 61.75% for 2009
- Last Day to Vote for the Best IR Program and Best IR Officer
- Last Days to Vote for Companies in the 2010 IR Global Rankings
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
China Medical Technologies, Inc. (NASDAQ: CMED) today announced that the Company has received approval for its SPR-based analysis system from the State Food and Drug Administration of China.
The SPR System utilizes Surface Plasmon Resonance technology, a leading biosensor technology in molecular biology. Human papillomavirus, a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer, can be detected by adding pathological samples on the HPV-DNA biosensor chip and analyzing the HPV-DNA chip with the SPR System. The SPR System is label-free with high throughput, high speed and a high degree of automation. The detection results can be displayed on a real-time and online basis. The SPR System can be used in various potential clinical diagnostic applications, such as the detection of biomarkers related to infectious diseases, cancers, cardiovascular disorders and immune system disorders.
China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders.
Related Categories
Corporate NewsStocks Mentioned
+0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
